Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 237

Zuellig brings Klinify into its clinic

Zuellig Pharma has paid an undisclosed amount for portfolio company Klinify after investing in the healthcare data software provider two years ago.

Jun 5, 2019

Daily deal net: June 5, 2019

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Jun 5, 2019

Inhibrx looks to inhabit public markets spot

The WuXi Biologics, Eli Lilly and Alexandria Real Estate Equities-backed cancer therapy developer is targeting $74.7m in its IPO.

Jun 5, 2019

Karuna clears path to $75m IPO

Having confidentially filed in late April, Karuna Therapeutics has publicly applied for an initial public offering that would raise $75m and provide exits to Nan Fung and PureTech Health.

Jun 5, 2019

Global Fashion Group gets ready for $338m IPO

Rocket Internet, Access Industries and Tengelmann-backed fashion e-commerce marketplace GFG could float in Germany next month.

Jun 4, 2019

The RealReal sets up shop for IPO

The second-hand luxury goods marketplace has set down a $100m target for an initial public offering that would offer an exit for Novel TMT Ventures.

Jun 4, 2019

NEVS charges up Protean Electric purchase

National Electric Vehicle Sweden has acquired the in-wheel electric motor producer, enabling Zhejiang VIE Science & Technology and Tianjin THSG Corporation to exit.

Jun 4, 2019

Twitter absorbs Fabula AI

USI-founded fake news detection technology developer Fabula AI has been scooped up by Twitter, which will employ the spinout's talent to remove spam and abuse from its platform.

Jun 4, 2019

Adaptive Biotechnologies switches to IPO mode

The immunotherapy technology developer has set a $230m target for an initial public offering that would offer exits to LabCorp, Illumina, Celgene and BD Biosciences.

Jun 3, 2019

Morphic moves toward public markets

Novo, GlaxoSmithKline, Pfizer, AbbVie, ShangPharma and Schrödinger are all in line for exits following the small-molecule drug developer's decision to file for an $86.3m initial public offering.

Jun 3, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here